ClinicalTrials.gg
CompletedNCT03217422AMBERUpdated Feb 19, 2026

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

A Phase 2/3 interventional study of VAY736 and Placebo in Autoimmune Hepatitis, sponsored by Novartis Pharmaceuticals. Completed at 28 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 10 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Nov 2024.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

VAY736 dose testing; VAY736 efficacy and safety testing.

Read the detailed description

This is a randomized, placebo-controlled, double-blind dose range study in autoimmune hepatitis. The study population consists of female and male adult autoimmune hepatitis patients with incomplete response or intolerant to standard treatment of care. The diagnosis of autoimmune hepatitis has to fulfill the IAIHG criteria and must be confirmed by liver histology.

Patients will be randomly assigned to different doses of VAY736 or placebo. The primary analysis is planned at 24 weeks. A subsequent study part will then test the efficacy and safety of VAY736 in a parallel group design. For this part of the trial a new group of autoimmune hepatitis patients will be enrolled.

02

Conditions studied

  • Autoimmune Hepatitis

Browse trials for

Keywords

  • Type 1
  • Type 2
  • autoimmune hepatitis
  • AIH
03

In context

Hepatitis, Autoimmune

82 studies on the registry are indexed under Hepatitis, Autoimmune; 24 are open to participants now.

This study's enrollment of 68 is above the median of 48 across 42 interventional studies indexed under Hepatitis, Autoimmune.

Browse Hepatitis, Autoimmune studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. AIH diagnosed per International Hepatitis Group
  2. Liver with Ishak modified HAI indicating active AIH
  3. Incomplete response to OR intolerance of standard therapy (per AASLD)

Key Exclusion Criteria

  1. Prior use of any B-cell depleting therapy (e.g., rituximab or other anti-CD20 mAb, anti-CD22 mAb or anti-CD52 mAb) within 1 year prior to Screening or as long as B-cell count \<50 cells/µL
  2. Required regular use of medications with known hepatotoxicity
  3. Decompensated cirrhosis
  4. Diagnosis of overlap syndrome with AIH (e.g., AIH+PBC, AIH+PSC).
  5. Drug related AIH at screening or a history of drug related AIH.
  6. History of drug abuse or unhealthy alcohol use
  7. History of of any organ system
  8. Pregnant or nursing (lactating) women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Arm 1

    VAY736 Dose 1

    Biological: VAY736

  • Experimental
    Arm 2

    VAY736 Dose 2

    Biological: VAY736

  • Experimental
    Arm 3

    VAY736 Dose 3

    Biological: VAY736

  • Placebo comparator
    Arm 4

    Placebo

    Other: Placebo

Interventions

  • BiologicalVAY736

    VAY736

  • OtherPlacebo

    Placebo control with conversion to active VAY736

06

What researchers measure

Primary outcomes

  1. ALT (Alanine aminotransferase) normalization

    Difference in ALT normalization

    Time frame: Week 24

Secondary outcomes

  1. ALT normalization by dose

    VAY736 dose-response

    Time frame: Week 24

07

Study locations

28 sites
  • Southern California Research Center
    Coronado, California 92118, United States
  • Inland Empire Liver Foundation
    Rialto, California 92377, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • St. Lukes Advanced Liver Therapies
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    CABA, Buenos Aires C1056ABI, Argentina
  • Novartis Investigative Site
    CABA, C1181ACH, Argentina
  • Novartis Investigative Site
    Ghent, 9000, Belgium
  • Novartis Investigative Site
    Edmonton, Alberta T6G 2B7, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2C4, Canada
  • Novartis Investigative Site
    Montreal, Quebec H2X 1R9, Canada
  • Novartis Investigative Site
    Prague, 12000, Czechia
  • Novartis Investigative Site
    Würzburg, Bavaria 97080, Germany
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hanover, 30625, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Sapporo, Hokkaido 0068555, Japan
  • Novartis Investigative Site
    Takamatsu, Kagawa-ken 760 8557, Japan
  • Novartis Investigative Site
    Itabashi Ku, Tokyo 173 8606, Japan
  • Novartis Investigative Site
    Barcelona, 08036, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
  • Novartis Investigative Site
    Bern, 3010, Switzerland
  • Novartis Investigative Site
    Birmingham, West Midlands B15 2TH, United Kingdom
  • Novartis Investigative Site
    London, SE5 9RS, United Kingdom
  • Novartis Investigative Site
    Newcastle upon Tyne, NE1 4LP, United Kingdom
  • Novartis Investigative Site
    Nottingham, NG7 2UH, United Kingdom
  • Novartis Investigative Site
    Oxford, OX3 9DU, United Kingdom
08

References and documents

Publications

  • Cholankeril G, Vierling JM. The clinical imperative of a complete biochemical response to immunosuppression in autoimmune hepatitis: Close is not good enough! Hepatology. 2024 Mar 1;79(3):529-531. doi: 10.1097/HEP.0000000000000597. Epub 2023 Sep 18. No abstract available. PubMed 37722131 ↗
  • Chung YY, Rahim MN, Heneghan MA. Autoimmune hepatitis and pregnancy: considerations for the clinician. Expert Rev Clin Immunol. 2022 Apr;18(4):325-333. doi: 10.1080/1744666X.2022.2044307. Epub 2022 Mar 2. PubMed 35179437 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Dec 2023, 70 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2017
First posted
Jul 14, 2017
StartActual
Feb 15, 2018
Primary completionActual
Dec 28, 2023
CompletionActual
Dec 17, 2025
Results delay requested
Nov 25, 2024
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03217422
Responsible party
Sponsor
First posted
Jul 14, 2017
Start date
Feb 15, 2018
Primary completion
Dec 28, 2023
Completion
Dec 17, 2025
Last update
Feb 19, 2026

Study contacts

Study Director
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion